Delphia (Usa) Inc. Mersana Therapeutics, Inc. Transaction History

Delphia (Usa) Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$3.08 - $9.55 $22,708 - $70,412	-7,373 Reduced 30.26%	16,992 $55,000
Q1 2023 May 15, 2023	SELL	$4.0 - $7.02 $34,688 - $60,877	-8,672 Reduced 26.25%	24,365 $100,000
Q4 2022 Feb 14, 2023	BUY	$5.65 - $7.86 $103,445 - $143,908	18,309 Added 124.31%	33,037 $193,000
Q3 2022 Nov 14, 2022	BUY	$4.63 - $8.0 $68,190 - $117,824	14,728 New	14,728 $100,000

125

116M

233K

457K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $52.5M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Delphia (Usa) Inc., based on Form 13F filings with the SEC.

Stay updated on Delphia (Usa) Inc. with notifications on news.